Business Context and Reporting Period
This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on March 9, 2017, reporting events occurring on March 6 and March 7, 2017. The filing concerns the resolution of ongoing patent litigation regarding the Company's product Trokendi XR (extended-release topiramate) capsules.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a material definitive agreement and does not contain financial statement data.
Material Changes and Agreements
- Settlement Agreement: On March 6, 2017, Supernus entered into a binding term sheet with Actavis Laboratories, FL, Inc., Actavis Pharma, Inc., and Watson Laboratories, Inc. (collectively "Actavis," a subsidiary of Teva Pharmaceuticals Industries, Ltd.).
- Resolution of Litigation: The agreement settles patent litigation arising from Actavis's Abbreviated New Drug Application (ANDA) seeking approval for a generic version of Trokendi XR.
- Licensing Terms: Supernus will grant Actavis a non-exclusive license to market the generic product beginning on January 1, 2023, or earlier under certain circumstances.
- Revenue Stream: Actavis will make royalty payments to Supernus during the term of the license agreement.
- Company Rights: Supernus retains the right to market an authorized generic product and to grant additional licenses to third parties.
Outlook, Risks, and Management Commentary
Management announced the settlement via a press release on March 7, 2017. The agreement eliminates the uncertainty of the ongoing litigation regarding the Patents-in-Suit (U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; and 8,992,989). The filing does not provide specific forward-looking guidance on financial performance beyond the establishment of the royalty payment structure.
Investor Verification Checklist
- Verify the specific terms of the royalty payments and the conditions under which the license start date may occur prior to January 1, 2023.
- Confirm the status of the authorized generic product rights retained by Supernus.
- Review the full text of the settlement and license agreements to understand any exclusivity limitations or additional obligations.
- Monitor future filings for the execution of the final settlement and license agreements referenced in the term sheet.